Neurocrine CMO Eiry Roberts to step down; Sanjay Keswani named successor June 2, 2025

NEUROCRINE BIOSCIENCES INC

Dr. Eiry Roberts transitions from CMO to Strategic Advisor to the CEO, effective June 2, 2025 through Dec 31, 2025.
Dr. Sanjay Keswani will succeed Dr. Roberts as Chief Medical Officer, effective June 2, 2025.
Dr. Roberts receives annual base salary of $731,400 and target bonus of 60% of base pay in new advisory role.
Outstanding equity awards continue vesting; severance terms substantially unchanged from prior agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Eiry W. Roberts

Strategic Advisor to the CEO

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2025-06-02
Successor: Sanjay Keswani
Filed: May 30, 2025, 7:59 PM ET

Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.

Appointed

Sanjay Keswani

Chief Medical Officer

NBIX · NEUROCRINE BIOSCIENCES INC

Effective: 2025-06-02
Filed: May 30, 2025, 7:59 PM ET

Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eiry W. Roberts changed role as Strategic Advisor to the CEO at NEUROCRINE BIOSCIENCES INC.

Action: transitioned
Role: Strategic Advisor to the CEO

Exact text from the filing

Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sanjay Keswani was appointed as Chief Medical Officer at NEUROCRINE BIOSCIENCES INC.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of the Company, effective June 2, 2025.

View on SEC.gov

NEUROCRINE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000914475-25-000139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.